Epizyme Announces Appoint Chief Medical Officer

Dr. Hedrick brings extensive experience in both the development and post-approval clinical management of innovative cancer therapies that target both hematologic malignancies and solid tumors. Eric was most recently at Pharmacyclics as VP of Oncology Development and Interim Chief Medical Officer, responsible for clinical development of the oncology portfolio, including the Bruton's tyrosine kinase inhibitor, ibrutinib. Prior to Pharmacyclics, Eric held a number of positions in clinical development and medical affairs at Genentech, including oversight of multiple aspects of the development of Rituxan(R) (rituximab) and Avastin(R) (bevacizumab).

Robert Gould, Ph.D., CEO and President, said, "Epizyme is committed to the development of personalized therapeutics for patients with genetically-defined cancers. Dr. Hedrick brings a track record of success in developing innovative therapeutics for cancer patients. His appointment is another important step forward for Epizyme as we build a new leading biopharma company."

"Epizyme's personalized therapeutics represent potential breakthrough medicines for patients with genetically-defined cancers. I am excited to be joining the company as we advance our lead programs and pipeline," said Eric Hedrick, M.D., Chief Medical Officer.